Log in or Sign up for Free to view tailored content for your specialty!
Chronic Hepatitis News
Study highlights 'substantial need' to provide DAA therapy to all patients with HCV
Direct-acting antiviral treatment significantly lowered the risk for mortality and liver and non-liver outcomes in patients with chronic hepatitis C virus infection, regardless of disease stage, researchers reported.
D-LIVR topline results: Lonafarnib all-oral, combination regimens boost response in HDV
Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced.
Log in or Sign up for Free to view tailored content for your specialty!
Hepatologists’ role in HCV care, elimination ‘remains one of advocacy’
WASHINGTON — A leading expert in hepatology called for fellow specialists to embrace a role of education, advocacy and support as part of a proposed national hepatitis C virus elimination program presented during The Liver Meeting.
Vosevi effective rescue therapy in patients with chronic HCV after DAA treatment failure
WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.
The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality
The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.
Hepatitis B Foundation names Baruch S. Blumberg Prize winner
The Hepatitis B Foundation has awarded Stephen Urban, PhD, the 2023 Baruch S. Blumberg Prize for his development of bulevirtide, the first drug approved for the treatment of hepatitis D.
Recent injection drug use linked to HCV reinfection after DAA treatment
WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.
HCV care must ‘move away from the ivory tower’ to achieve elimination
WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.
Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050
WASHINGTON — An accelerated, nationally organized plan to eliminate hepatitis C virus in the United States could save more than 90,000 lives and nearly $60 billion by 2050, according to a health economics expert at The Liver Meeting.
ReLink programs led to treatment, engagement in nearly 20% of patients with untreated HCV
WASHINGTON — Implementation of care re-engagement programs led to the treatment of more than 700 patients with untreated hepatitis C virus infection who had been lost to follow-up, according to research presented at The Liver Meeting.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read